Dr. Haas on Adjuvant VEGF-Targeted Therapy in RCC

Video

Naomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).

Naomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).

There are currently 8 adjuvant clinical trials in the United States and Europe, Haas explains. In the last 2 years, 2 of those trials have reported data. One of them, the ASSURE trial, which was a randomized study of sunitinib (Sutent), sorfaenib (Nexavar), or placebo for 1 year. Patients enrolled on the trial were divided by cohorts of intermediate- and high-risk classification with clear cell and non-clear cell histology. Following approximately 1300 patient accrual, there was a higher discontinuation rate than expected due to toxicity and intolerability. Due to this, the study was amended to include patients with a -1 dose level with a mandatory dose escalation.

The second study, the S-TRAC trial, enrolled patients with clear cell histology with a slightly higher risk stratification who were treated with 1 year of full-dose sunitinib versus placebo. The study was not amended; all patients started at the full dosage. A dose reduction was permitted at 37.5, Haas says. This trial had an endpoint of disease-free survival, which was reported as positive, Haas explains.

<<<

View more from the 2016 International Kidney Cancer Symposium

Recent Videos
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
© 2025 MJH Life Sciences

All rights reserved.